Obesity Drugs: What I Would Do If It Were Up to Me
I would request a randomized head-to-head study lasting three years of the obesity drug in question vs Allergan’s LapBand procedure.
Any drug that achieved non-inferiority to LapBand in cumulative weight loss and CV-related morbidity/mortality would be deemed worthy of approval. I would allow a wide non-inferiority margin because LapBand is a very good product.
JMHO, FWIW
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.